Max Van Ingen
About Max Van Ingen
Max Van Ingen is a Process Engineer at Kite Pharma, specializing in the development of cancer treatments. He has extensive experience in laboratory and manufacturing roles within the pharmaceutical and biotechnology sectors.
Work at Kite Pharma
Max Van Ingen currently serves as a Process Engineer at Kite Pharma since 2021, focusing on the development of cancer treatments. He has previously held the role of Technical Trainer at Kite Pharma starting in 2020, where he contributed to training initiatives for staff in Hoofddorp, Noord-Holland. Additionally, he worked as a Cell Therapy Specialist II from 2018 to 2020, where he was involved in the production of personalized medicine treatments for non-Hodgkin lymphoma. His experience also includes a brief tenure as an International Appointee Cell Therapy Specialist II in El Segundo, California, in 2019.
Education and Expertise
Max Van Ingen has a diverse educational background in the sciences and management. He earned a Bachelor of Applied Science in Applied Science with a specialization in Life Science from Fontys Hogescholen from 2009 to 2013. He also studied Molecular Biology, Cell Biology, and Microbiology at ROC Eindhoven from 2005 to 2009. Additionally, he completed a year at Avans Hogeschool Breda, focusing on Retail Management and Small Business, achieving a Minor in Innovative Entrepreneurship. His education supports his expertise in biotechnology and pharmaceutical processes.
Background
Max Van Ingen's career began with various laboratory technician roles, including a trainee position at Coca-Cola Enterprises in 2008 and subsequent roles at Eindhoven University of Technology and Hycult Biotech. He transitioned to the pharmaceutical industry, working as an Associate Manufacturing Operator at The Janssen Pharmaceutical Companies of Johnson & Johnson from 2015 to 2017. His experience includes handling large-scale cell culture batches, showcasing his capabilities in biotechnological manufacturing processes.
Achievements
Max Van Ingen co-authored an article in the journal Neuroscience, contributing to research in the field of induced Pluripotent Stem Cells (iPSC)-derived neurons. His work in the pharmaceutical industry includes specialization in compounding complex sterile nanoparticle and liposomal injectable chemotherapy products. This indicates his strong background in advanced pharmaceutical formulations and his commitment to developing innovative treatment solutions.